Related Experiment Video
Updated: Aug 13, 2026
A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo
Published on: January 10, 2025
Recombinant human erythropoietin in a triplet pregnancy: a case report
Georgios Lialios1, Athanasios Kallitsaris, Konstantinos L Bourantas
1Department of Obstetrics and Gynecology, Medical School, University of Thessalia, Greece. lialiosg@hotmail.com
Background:
Women carrying triplets are at greater risk for both anemia, due to the increased demands of the developingfetuses, and peripartum hemorrhage. Jehovah's witnesses are a unique obstetric population since women of this faith refuse blood transfusion.
Case:
A Jehovah's Witness with a triplet pregnancy was successfully administered recombinant human erythropoietin (rHuEpo), 200 IU/kg 3 times per week subcutaneously, in order to correct her peripartum anemia. No side effects were observed during rHuEpo therapy, and the patient delivered healthy triplets.
Conclusion:
rHuEpo can be safely administered, with a beneficial effect in pregnancy, and seems to be an effective option in preventing transfusions as demonstrated in this case in a Jehovah's Witness.